The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
Status:
Completed
Trial end date:
1999-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the
buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal
system and immediate release oxycodone/acetaminophen in subjects with osteoarthritis pain
inadequately treated with non-opioid analgesics. The double-blind treatment intervention
duration is 60 days.